Staghorn renal stones: what the urologist needs to know.


Journal

International braz j urol : official journal of the Brazilian Society of Urology
ISSN: 1677-6119
Titre abrégé: Int Braz J Urol
Pays: Brazil
ID NLM: 101158091

Informations de publication

Date de publication:
Historique:
received: 10 02 2020
accepted: 25 03 2020
pubmed: 28 3 2020
medline: 28 1 2021
entrez: 28 3 2020
Statut: ppublish

Résumé

Patients with staghorn renal stones are challenging cases, requiring careful preoperative evaluation and close follow-up to avoid stone recurrence. In this article we aim to discuss the main topics related to staghorn renal stones with focus on surgical approach. Most of staghorn renal stones are composed of struvite (magnesium ammonium phosphate) and are linked to urinary tract infection by urease-producing pathogens. Preoperative computed tomography scan and careful evaluation of all urine cultures made prior surgery are essential for a well-planning surgical approach and a right antibiotics choice. Gold standard surgical technique is the percutaneous nephrolithotomy (PCNL). In cases of impossible percutaneous renal access, anatrophic nephrolithotomy is an alternative. Shockwave lithotripsy and flexible ureteroscopy are useful tools to treat residual fragments that can be left after treatment of complete staghorn renal stone. PCNL can be performed in supine or prone position according to surgeon's experience. Tranexamic acid can be used to avoid bleeding. To check postoperative stone-free status, computed tomography is the most accurate imaging exam, but ultrasound combined to KUB is an option. Intra-operative high-resolution fluoroscopy and flexible nephroscopy have been described as an alternative for looking at residual fragments and save radiation exposure. The main goals of treatment are stone-free status, infection eradication, and recurrence prevention. Long-term or short-term antibiotic therapy is recommended and regular control imaging exams and urine culture should be done.

Identifiants

pubmed: 32213203
doi: 10.1590/S1677-5538.IBJU.2020.99.07
pii: IBJU20209907
pmc: PMC7527092
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

927-933

Informations de copyright

Copyright® by the International Brazilian Journal of Urology.

Déclaration de conflit d'intérêts

None declared.

Références

Eur Urol. 2016 Apr;69(4):e85
pubmed: 27301798
Urolithiasis. 2019 Oct 15;:
pubmed: 31616985
J Urol. 2013 May;189(5):1757-61
pubmed: 23123376
Urolithiasis. 2016 Nov;44(6):551-557
pubmed: 27032961
PLoS One. 2019 Jan 31;14(1):e0206810
pubmed: 30703102
J Urol. 2006 Jan;175(1):162-5; discussion 165-6
pubmed: 16406897
J Urol. 2016 Oct;196(4):1153-60
pubmed: 27238616
Eur Urol. 2015 Jan;67(1):125-137
pubmed: 25064687
World J Urol. 2016 Aug;34(8):1163-8
pubmed: 26659063
Br J Urol. 1991 Aug;68(2):122-4
pubmed: 1884136
J Urol. 2005 Feb;173(2):469-73
pubmed: 15643212
Urology. 2013 Dec;82(6):1240-4
pubmed: 24063939
Urol Clin North Am. 1981 Jun;8(2):265-76
pubmed: 7268961
Iran J Med Sci. 2019 Nov;44(6):457-464
pubmed: 31875080
J Endourol. 2016 Sep;30(9):975-81
pubmed: 27368353
Int J Antimicrob Agents. 2002 Jun;19(6):488-98
pubmed: 12135839
J Urol. 1988 Aug;140(2):318-24
pubmed: 3294442
Nat Rev Urol. 2014 Jun;11(6):333-41
pubmed: 24818849
Nat Rev Urol. 2013 Jan;10(1):2
pubmed: 23165402
J Endourol. 1993 Aug;7(4):293-5
pubmed: 8252021
N Engl J Med. 1984 Sep 20;311(12):760-4
pubmed: 6472365
J Endourol. 1999 Nov;13(9):653-8
pubmed: 10608517
Eur Urol. 1991;20(3):243-7
pubmed: 1726639
J Endourol. 2019 Nov;33(11):954-959
pubmed: 31436119
J Endourol. 2016 Jul;30(7):771-7
pubmed: 24251429
J Urol. 1997 Mar;157(3):780-6
pubmed: 9072566
J Endourol. 2017 May;31(5):533-537
pubmed: 28355093
Urolithiasis. 2017 Dec;45(6):603-608
pubmed: 28357451
Ann Urol (Paris). 2005 Feb;39(1):16-29
pubmed: 15830551
J Urol. 2016 Oct;196(4):1161-9
pubmed: 27238615
Ren Fail. 2018 Nov;40(1):357-362
pubmed: 29658394
Eur Urol. 2016 Mar;69(3):468-74
pubmed: 26318710

Auteurs

Fabio C M Torricelli (FCM)

Divisão de Urologia, Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo, SP, Brasil.

Manoj Monga (M)

Stevan B, Streem Center for Endourology & Stone Disease, Glickman Urological & Kidney Institute, The Cleveland Clinic, Cleveland, OH, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH